Core Insights - The announcement from Lijun Pharmaceutical (01513) indicates that a total of 194 products from the company have been included in the National Medical Insurance Catalog for 2025, with 92 classified as Category A and 102 as Category B [1] Group 1 - The inclusion of Lijun Pharmaceutical's products in the National Medical Insurance Catalog is significant for the company's market positioning and revenue potential [1] - Notably, the injectable Aripiprazole microspheres have been included in the catalog for the first time through negotiations, which may enhance its market access [1] - The injectable Triptorelin acetate microspheres have received an additional indication, potentially expanding its usage and sales opportunities [1] Group 2 - The injectable Esomeprazole sodium has successfully renewed its contract, ensuring continued reimbursement and market presence [1]
丽珠医药产品纳入国家医保目录